The prevalence of the mutation in codon 249 of the P53 Gene in Patients with Hepatocellular Carcinoma (HCC) in Turkey

Journal of Gastrointestinal Cancer

Volumn 41, Issue 3, 2010, Pages 185-189

  Özdemir, Filiz Türe ^a   Tiftikci, Arzu ^b   Sancak, Seda ^a   Eren, Fatih ^a   Tahan, Veysel ^a   Akın, Hakan ^a   Gündüz, Feyza ^a   Kedrah, Ala Eldeen ^a   Üstündağ, Yücel ^c   Avşar, Erol ^a   Tözün, Nurdan ^b   Özdoğan, Osman ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b ACIBADEM UNIVERSITY   (Turkey)

^c ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Aflatoxin; Chronic hepatitis B; Cirrhosis; Hepatocellular cancer; P53 codon 249

Indexed keywords

AFLATOXIN; DNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE MUTATION; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TURKEY (REPUBLIC);

EID: 78149467042     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-010-9140-5     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(29):74-108.
2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):5-16.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-17.
4. Özer B, Serin E, Yilmaz U, et al. Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey. Turk J Gastroenterol. 2003;14(2):85-90.
5. Stern MC, Umbach DM, Yu MC, et al. Hepatitis B, aflatoxin B1 and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Biomark Prev. 2001;10:617-25.
6. Yan RQ, Su JJ, Huang DR, et al. Human hepatitis B virus and hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflotoxin B1. Cancer Res Clin Oncol. 1996;122:289-95.
7. Kirk GD, Camus-Randon AM, Mendy M, et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from the Gambia. J Natl Cancer Inst. 2000;92(2):148-53.
8. Dong-Dong L, Xi-Ran Z. Plasma 249Ser p53 mutation in patients with hepatocellular carcinoma residing in a high risk area. J Cell Mol Med. 2003;7(1):89-92.
9. Jackson PE, Kuang SY, Wang JB, et al. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis. 2003;24(10):1657-63.
10. Szymanska K, Lesi OA, Kirk GD, et al. Ser249 TP53 mutation in tumor and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer. 2004;110:374-9.
11. Igetei R, Otegbayo JA, Ndububa DA, Lesi OA, Anumudu CI, Hainaut P, et al. Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cell-free DNA. Ann Hepatol. 2008;7(4):339-44.
12. Öztürk M et al. P53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet. 1991;338:1356-59.
13. Jackson PE, Qian GS, Friesen MD, Zhu YR, Lu P, Wang JB, et al. Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res. 2001;61:33-5.
14. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002;21:7435-51.
15. Niu ZS, Li BK, Wang M. Expression of p53 and C-myc genes and its clinical relevance in the hepatocellular carcinomatous and pericarcinomatous tissues. World J Gastroenterol. 2002; 8:822-6.
16. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinoma. Nature. 1991;350:427-8.
17. Li D, Cao Y, He LJ, Gu JR. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis. 1993;14:169-73.
18. Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ, Xie JP, Thorgeirsson SS. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res. 1994;54:281-5.
19. Deng ZL, Ma Y. Aflatoxin sufferer and p53 gene mutation in hepatocellular carcinoma. World J Gastroenterol. 1998;4:28-9.
20. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 1999;59:71-3.
21. Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med. 1996;2:1033-5.
22. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 1996;2:1035-7.
23. Huang X-H, Sun L-H, Lu D-D, Sun Y, Ma L-J, Zhang X-R, et al. Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China. World J Gastroenterol. 2003;9 (4):692-95.
24. Katiyar S, Dash BC, Thakur V, Guptan RC, Sarin SK, Das BC. P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India. Cancer. 2000;88:1565-73.
25. Yang M, Zhou H, Kong RY, Fong WF, Ren LQ, Liao XH, et al. Mutations at codon 249 of p53 gene in human hepatocellular carcinomas from Tongan, China. Mutat Res. 1997;381:25-9.
26. Rashid A, Wang JS, Qian GS, Lu BX, Hamilton SR, Groopman JD. Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations. Br J Cancer. 1999;80:59-66.
27. Shimizu Y, Zhu JJ, Han F, Ishikawa T, Oda H. Different frequencies of p53 codon-249 hot-spot mutations in hepatocellular carcinomas in Jiang-su Province of China. Int J Cancer. 1999;82:187-90.
28. Vautier G, Bomford AB, Portmann BC, Metivier E, Williams R, Ryder SD. P53 mutations in British patients with hepatocellular carcinoma: clustering in genetic hemochromatosis. Gastroenterology. 1999;117:154-60.
29. Boix-Ferrero J, Pellin A, Blesa R, Adrado M, Llombart-Bosch A. Absence of p53 gene mutations in hepatocarcinomas from a Mediterranean area of Spain. A study of 129 archival tumour samples. Virch Arch. 1999;434:497-501.
30. Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, et al. p53 mutations, chronic hepatitis B virus infection and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res. 1997;57:3471-7.
31. Shen HM, Ong CN. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res. 1996;366:23-44.
32. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res. 1999;59:2557-61.
33. Smela ME, Currier SS, Bailey EA, Essigmann JM. The chemistry and biology of aflatoxin B1: from mutational spectrometry to carcinogenesis. Carcinogenesis. 2001;22(4):535-45.
34. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007;26:2166-76.
35. Wild CP, Montesano R. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett. 2009; PMID: 19345001.
36. Kirk GD, Lesi OA, Mendy M, Szymañska K, Whittle H, Goedert JJ, et al. 249 (ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene. 2005;24(38):5858-67.